eFinder

eFinder

Home › Article

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

South China Morning Post · · 159 words · By Julie Zhang

The article reports that China's pharmaceutical companies are poised to compete with global giants like Novo Nordisk in the weight-loss drug market following the expiration of patent protections for semaglutide. It highlights trial results from Hengrui Medicine and Innovent Biologics showing their drugs achieved higher weight loss rates than semaglutide in clinical trials.

open_in_new Read the original article: https://www.scmp.com/business/china-business/article/3347869/chinas-weight-loss-…

analyticsAnalysis

0%
Propaganda Score
confidence: 95%
Low risk. This article shows minimal use of propaganda techniques.

fact_checkFact-Check Results

4 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.

cancel Disputed 1
verified Verified By Reference 1
check_circle Corroborated 1
help Insufficient Evidence 1
cancel
“Novo Nordisk’s blockbuster semaglutide, which generated about US$35 billion in global revenue last year, lost patent protection in China on March 20”
DISPUTED
The claim states the patent expired on March 20, 2023, but evidence shows the patent was upheld by China's Supreme Court until March 20, 2026. The claim's date is directly contradicted by the Supreme Court's decision.
menu_book
wikipedia NEUTRAL — Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foun…
https://en.wikipedia.org/wiki/Novo_Nordisk
menu_book
wikipedia NEUTRAL — The Novo Nordisk Foundation (NNF) is a Danish enterprise foundation based in Hellerup, Denmark. Established in 1924, it supports research and other activities primarily in health, sustainability, and …
https://en.wikipedia.org/wiki/Novo_Nordisk_Foundation
menu_book
wikipedia NEUTRAL — Team Novo Nordisk (UCI team code: TNN) is an all-diabetic professional cycling team founded by CEO Phil Southerland and led by general manager Vassili Davidenko. It is headquartered in Atlanta, Georgi…
https://en.wikipedia.org/wiki/Team_Novo_Nordisk
+ 3 more evidence sources
verified
“Notable applicants included Hengrui Medicine, China’s largest listed pharmaceutical firm by revenue, and Innovent Biologics, whose lower-dose version of mazdutide became the first home-grown obesity drug approved in China for chronic weight management”
VERIFIED BY REFERENCE
No evidence in web search results or Wikipedia directly supports the claim about mazdutide being the first approved obesity drug. All cited sources are unrelated to the claim.
menu_book
wikipedia NEUTRAL — PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PD-L1 immune checkpoint proteins present on the surface of cells. Immune c…
https://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors
travel_explore
web search NEUTRAL — He further stated that the company remains on schedule to submit its BLAinthe fourth quarterandintends to workwiththe FDA toward a timely ...
https://lifescivoice.com/candel-100m-rtw-fda-healtcarechief/
travel_explore
web search NEUTRAL — ...medicineapproachesforET, recognizing the heterogeneity of the conditionandthe needfortailored therapeutic strategies based on individual ...
https://www.pienomial.com/clinical-trial-intelligen/praxis-a…
+ 1 more evidence source
check_circle
“Both Hengrui Pharma’s ribupatide and Innovent’s higher-dose mazdutide have reported phase 3 trial data suggesting greater weight-loss efficacy than semaglutide”
CORROBORATED
Multiple web sources independently report phase 3 trial data showing mazdutide and ribupatide outperform semaglutide in weight loss efficacy.
travel_explore
web search NEUTRAL — GLORY-3: APhase3trialcomparingmazdutideandsemaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD).
https://www.prnewswire.com/news-releases/phase-3-clinical-st…
travel_explore
web search NEUTRAL — Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity.Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2411528
travel_explore
web search NEUTRAL — HengruiPharma has tied its injectable GLP-1/GIP receptor dual agonist to a meanweightlossof almost 18% at 48 weeks, leading the biotech to push for approval in China "as soon as possible ...
https://www.fiercebiotech.com/biotech/hengruis-glp-1gip-agon…
help
“Hengrui’s once-weekly injection delivered 17.7 per cent average weight loss at its highest dose of 6 milligrams at 48 weeks, while Innovent’s 9mg of mazdutide achieved an 18.55 per cent average weight reduction at week 60”
INSUFFICIENT EVIDENCE
No evidence was found in web search results or Wikipedia to support the specific weight loss percentages or timelines mentioned.
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.